Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

被引:23
作者
Lambert, Bieke [1 ]
Sturm, Emiel [2 ]
Mertens, Jeroen [1 ]
Oltenfreiter, Ruth [1 ]
Smeets, Peter [3 ]
Troisi, Roberto [4 ]
Van Vlierberghe, Hans [5 ]
Defreyne, Luc [2 ]
机构
[1] Ghent Univ Hosp, Dept Nucl Med, B-9000 Ghent, Belgium
[2] Ghent Univ Hosp, Dept Vasc & Intervent Radiol, B-9000 Ghent, Belgium
[3] Ghent Univ Hosp, Dept Radiol, B-9000 Ghent, Belgium
[4] Ghent Univ Hosp, Dept Hepatobiliary Surg & Liver Transplantat, B-9000 Ghent, Belgium
[5] Ghent Univ Hosp, Dept Gastroenterol & Hepatol, B-9000 Ghent, Belgium
关键词
Hepatocellular carcinoma (HCC); Liver; Microspheres; Y-90; Selective internal radiation therapy (SIRT); LIVER-TRANSPLANTATION; RADIOEMBOLIZATION; CHEMOEMBOLIZATION; MANAGEMENT; OUTCOMES; SAFETY;
D O I
10.1007/s00259-011-1881-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with Y-90 microspheres. Secondly, we investigated the urinary excretion of Y-90 following treatment. Methods We retrospectively reviewed all HCC patients referred to our department for Y-90 microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Results Forty-three HCC patients were referred for radio-embolization. Fourteen patients were excluded, mainly due to unfavourable Tc-99m-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with Y-90 microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Conclusion Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of Y-90 excreted in the urine.
引用
收藏
页码:2117 / 2124
页数:8
相关论文
共 23 条
[1]   Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with 99mTc-MAA accumulation in the anterior abdominal wall? [J].
Ahmadzadehfar, Hojjat ;
Moehlenbruch, Markus ;
Sabet, Amir ;
Meyer, Carsten ;
Muckle, Marianne ;
Haslerud, Torjan ;
Wilhelm, Kai ;
Schild, Hans Heinz ;
Biersack, Hans Juergen ;
Ezziddin, Samer .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (08) :1477-1484
[2]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[3]   Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer [J].
Coldwell, Douglas M. ;
Kennedy, Andrew S. ;
Nutting, Charles W. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03) :800-804
[4]   Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis [J].
El-Serag, Hashem B. ;
Rudolph, Lenhard .
GASTROENTEROLOGY, 2007, 132 (07) :2557-2576
[5]   Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres [J].
Gulec, Seza A. ;
Siegel, Jeffry A. .
JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (12) :2080-2086
[6]   Hepatic Structural Dosimetry in 90Y Microsphere Treatment: A Monte Carlo Modeling Approach Based on Lobular Microanatomy [J].
Gulec, Seza A. ;
Sztejnberg, Manuel L. ;
Siegel, Jeffry A. ;
Jevremovic, Tatjana ;
Stabin, Michael .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (02) :301-310
[7]   Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term Survival [J].
Hilgard, Philip ;
Hamami, Monia ;
El Fouly, Amr ;
Scherag, Andre ;
Mueller, Stefan ;
Ertle, Judith ;
Heusner, Till ;
Cicinnati, Vito R. ;
Paul, Andreas ;
Bockisch, Andreas ;
Gerken, Guido ;
Antoch, Gerald .
HEPATOLOGY, 2010, 52 (05) :1741-1749
[8]   Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis [J].
Inarrairaegui, Mercedes ;
Thurston, Kenneth G. ;
Bilbao, Jose I. ;
D'Avola, Delia ;
Rodriguez, Macarena ;
Arbizu, Javier ;
Martinez-Cuesta, Antonio ;
Sangro, Bruno .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2010, 21 (08) :1205-1212
[9]   Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma [J].
Lencioni, Riccardo ;
Llovet, Josep M. .
SEMINARS IN LIVER DISEASE, 2010, 30 (01) :52-60
[10]   A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization [J].
Lewandowski, R. J. ;
Kulik, L. M. ;
Riaz, A. ;
Senthilnathan, S. ;
Mulcahy, M. F. ;
Ryu, R. K. ;
Ibrahim, S. M. ;
Sato, K. T. ;
Baker, T. ;
Miller, F. H. ;
Omary, R. ;
Abecassis, M. ;
Salem, R. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (08) :1920-1928